HJY-02

HJY-02 is a preclinical **small interfering RNA** therapeutic being developed by Hygieia Pharmaceuticals for **Alzheimer's disease**. Public pipeline-style sources describe it as an **APP-targeting siRNA** intended to reduce expression of **amyloid precursor protein**, a key upstream source of beta-amyloid peptides implicated in Alzheimer pathology. Company-related disclosures further indicate that the program is designed for **CNS delivery**, with reported preclinical brain delivery to regions such as the hippocampus and the potential for **infrequent, possibly once-yearly dosing**. The asset appears to have remained at the **preclinical** stage in publicly accessible sources.